Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET-HF: Omecamtiv Mecarbil in HFrEF
NCT06736574Phase 3Recruiting
- Sponsor
- Cytokinetics
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Countries
- 10
01
Overview
A Phase 3 trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), sponsored by Cytokinetics. Started Dec 2024; status: recruiting.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06736574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736574.